SOURCE: Biochemics, Inc.

June 04, 2007 08:55 ET

Minor League Baseball Is Major Marketing Hit for VasoActive Topical Lotions

DANVERS, MA--(Marketwire - June 4, 2007) - "Why spend extra on mass-media advertising when you can reach almost as large an audience through other vehicles for a small fraction of the cost?" asks Stephen Cataldo, Director of Marketing, VasoActive Pharmaceuticals < >, distributors of uniquely formulated branded topical lotions for temporary relief for minor arthritis, muscle and joint pain, as well as relief from athlete's foot.

VasoActive products include Osteon arthritis pain relieving lotion, A-R Extreme for muscle and joint pain, along with Termin8, proven clinically effective in the treatment of athlete's foot with daily use.

"The combination of limited advertising resources and very specific retail territories demanded that we look for the most affordable way to reach large numbers of people. We decided for Minor League Baseball as a part of our marketing plan in 2006, which happily coincided with the best-ever season the Minor Leagues have ever had. While the plan still is in the early stage of implementation, from early indications we are optimistic that it will produce positive results," said Mr. Cataldo.

According to the Sports Network in October 2006, "Minor League Baseball set an all-time attendance record this season with a total of 39,887,755 fans going through the turnstiles at the 176 teams in the 15 affiliated leagues. That was an increase of 105,038 over the old mark that was set more than a half-century ago and an increase of 818,048 over the 2003 season. The former record was set in 1949 during the boom years following World War II when nearly every city and large town in the United States had its own Minor League team. That total of 39,782,717 was attained by 448 teams in 59 leagues."

"During the 2006 season, VasoActive experimented with promotional campaigns designed to increase visibility to help gain sales momentum," Mr. Cataldo continued. "These minor league ball parks in Michigan, New York, and New Jersey, helped use reach from four to six thousand fans per game."

Mr. Cataldo added, "The promotional campaigns continue in 2007. Last week produced some additional exposure at the home ballpark of the Trenton Thunder. Just in case you folks haven't heard, pitcher Roger Clemens, winner of seven Cy Young Awards, is returning to baseball -- and it happens that he is now pitching with the Trenton Thunder AA club, a New York Yankees farm club. Roger Clemens' home game event drew a record of 9,134 fans. Promoting our A•R Extreme product with the Thunder's video scoreboard, with the game televised nationally, gave us a substantial audience that day," explained Mr. Cataldo.

VasoActive products are available through retail outlets including Pathmark in New Jersey and New York, ShopRite, A&P, Super Fresh, Waldbaum's, Harmon Health and Beauty and 140 Meijer stores throughout Illinois, Indiana, Kentucky, Michigan and Ohio. Ordering can also be placed online via

Unique PENtoCORE® Technology Provides High Performance Results

The VasoActive family of topical products features a proprietary technology called PENtoCORE®, which provides safe, effective ointment penetration with less odor, less greasy feel and no residue. PENtoCORE® was developed by VasoActive's parent company, BioChemics, a drug delivery company with more than 15 years of research in improving effectiveness of topical lotions.

About VasoActive

VasoActive began operations in January 2003 as a division of BioChemics < >, a biopharmaceutical company engaged in transdermal and topical drug delivery systems. VasoActive is an early stage company established to commercialize, market and sell over-the-counter pharmaceutical products incorporating vaso active lipid encapsulated technology.


Certain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about the Company's industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Because such statements involve risks and uncertainties, the actual results and performance of the Company may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, the Company also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here; however, readers should review carefully reports of documents the Company files periodically with the SEC.

Contact Information

  • For further information contact:

    Matt Carter
    VasoActive Pharmaceuticals
    978-750-0090 x 28
    Email Contact